Osteomyelitis — Surgical Debridement and Dead-Space Management

Surgical Indications

Absolute Indications

• Chronic osteomyelitis with sequestrum or necrotic bone on imaging (Cierny-Mader Type III or IV)
• Septic nonunion with mobile fracture site and persistent sinus or drainage
• Failed previous debridement with recurrent sinus or positive cultures
• Pathological fracture through osteomyelitic bone

Relative Indications

• Cierny-Mader Type II superficial disease with exposed bone and failed local wound care
• Type I medullary osteomyelitis with persistent intramedullary infection after reaming and antibiotics
• Host optimisation completed in B-host with planned staged reconstruction

Contraindications

Absolute:

• C-host where surgical morbidity exceeds benefit (consider lifelong suppression or amputation)
• Active untreated systemic sepsis requiring immediate source control elsewhere

Relative:

• B-host with unoptimised comorbidities (smoking, glycaemic control, nutrition, vascular disease) — optimise first
• Small contained Type I lesion amenable to long-term oral antibiotics alone

Evidence Base

Radical surgical debridement combined with targeted antibiotics remains the cornerstone of treatment for chronic osteomyelitis. The Cierny-Mader classification guides both the extent of resection and the need for reconstruction. Modern series demonstrate that adequate resection to bleeding bone plus local antibiotic delivery and stability achieve infection-free union in 70-90% of cases when host factors are addressed, although exact rates vary by anatomic site and host class.

Cierny-Mader Classification

Anatomic Types

• Type I — Medullary: Infection confined to medullary canal; reaming or intramedullary lavage often adequate.
• Type II — Superficial: Cortical surface involvement with exposed bone; decortication to bleeding margins.
• Type III — Localised: Full-thickness sequestrum with surrounding involucrum; segmental resection feasible.
• Type IV — Diffuse: Circumferential cortical destruction, often with septic nonunion; requires stability and major reconstruction.

Physiologic Host Classes

• A-host: Normal immune and vascular status; best candidate for aggressive reconstruction.
• B-host: Compromised locally (smoking, vascular disease, radiation) or systemically (diabetes, malnutrition, immunosuppression); requires optimisation before definitive surgery.
• C-host: Treatment risk greater than disease burden; consider suppression or amputation.

Pre-operative Work-up

• Full history: duration of drainage, previous surgeries, antibiotic courses, smoking, diabetes, vascular symptoms.
• Laboratory: CRP, ESR, white cell count, albumin, HbA1c; blood cultures if systemic signs.
• Imaging: plain radiographs (sinus tracts, sequestrum, involucrum), MRI (extent of marrow and soft-tissue involvement), CT (cortical detail and sequestrum mapping), angiography if flap planned.
• Microbiology: deep bone biopsy or sinus tract culture if available; hold antibiotics until samples obtained.
• Host optimisation: smoking cessation (minimum 4-6 weeks), glycaemic control (HbA1c less than 8%), nutritional support (albumin greater than 3.5 g/dL), vascular assessment and revascularisation if indicated.

Positioning and Preparation

Patient position: Supine on radiolucent table with limb prepped free; tourniquet optional and used only for initial exposure if bleeding obscures visualisation. For lower limb, bump under ipsilateral hip.

Anaesthesia: General or regional; avoid local infiltration until cultures obtained.

Equipment: High-speed burr, curettes, rongeurs, osteotomes, pulsatile lavage, antibiotic-loaded PMMA (typically 2-4 g vancomycin + 2-4 g gentamicin or tobramycin per 40 g cement batch), external fixator set, fluoroscopy.

Consent: Discuss risk of recurrence (10-30% depending on host and extent), amputation, flap failure, nonunion, pathological fracture, prolonged antibiotics, multiple staged procedures.

Step-by-Step Radical Debridement

Step 1: Exposure and Sinus Excision

Use extensile approach (e.g. anteromedial for tibia) that incorporates all sinus tracts. Excise sinus tracts en bloc down to bone. Send tract tissue for culture and histology (rule out squamous-cell carcinoma in long-standing sinuses).

Step 2: Hardware Removal and Initial Debridement

Remove all loose or infected hardware. Send implant and surrounding tissue for culture. Perform initial soft-tissue debridement of all necrotic or fibrotic tissue until healthy, bleeding margins.

Step 3: Bone Resection to Paprika Sign

Identify sequestrum and resect with osteotomes or saw. Use high-speed burr and curettes to remove all sclerotic non-bleeding bone from cortical surfaces, endosteal canal and medullary cavity. Continue until every surface demonstrates the paprika sign (multiple punctate bleeding points from healthy bone).

Step 4: Deep Cultures

Obtain at least five deep samples from different locations: sequestrum, involucrum bed, medullary canal, soft-tissue membrane, and any remaining suspicious tissue. Label each and send for aerobic, anaerobic, fungal and mycobacterial culture. Do NOT administer systemic antibiotics until all samples are secured.

Step 5: Pulsatile Lavage and Haemostasis

Copious pulsatile lavage with 3-9 L of saline. Achieve haemostasis. Avoid excessive electrocautery that creates further necrosis.

Step 6: Dead-Space Management Decision

For defects less than 2-3 cm or in patients not candidates for major reconstruction, place antibiotic-loaded PMMA beads or a spacer. For larger defects in optimised hosts, plan staged Masquelet or transport.

Step 7: Stability

Apply external fixator or other stable construct if the debridement has created or revealed instability. Stability is essential for infection clearance.

Step 8: Soft-Tissue Coverage

If soft-tissue envelope is deficient, plan immediate or delayed flap coverage (local muscle flap or free flap) after debridement and before definitive bone grafting.

Local Antibiotic Delivery

Antibiotic-Loaded PMMA Beads or Spacers

• Mix 2-4 g vancomycin and/or 2-4 g gentamicin/tobramycin per 40 g PMMA batch.
• Form beads on wire or create a spacer shaped to the defect.
• Provides very high local antibiotic concentrations (greater than 100 times MIC) for 4-6 weeks.
• Maintains dead space and prevents haematoma colonisation.
• Must be removed within 6-8 weeks; prolonged retention risks biofilm on cement.

Other Local Carriers

• Calcium-sulphate pellets or composite carriers (absorbable, no removal needed).
• Collagen fleece or sponge impregnated with antibiotic.
• Choice depends on defect size, need for structural support and planned timing of definitive reconstruction.

Definitive Bone Reconstruction Options

Masquelet Induced-Membrane Technique

• Stage 1: radical debridement + antibiotic spacer.
• Stage 2 (6-8 weeks later): remove spacer, preserve induced membrane, fill with cancellous autograft (often RIA) mixed with antibiotic.
• Highly successful for defects up to 10-15 cm when soft-tissue envelope is healthy.

Bone Transport / Distraction Osteogenesis

• Indicated for larger defects (greater than 5-6 cm) or when autograft donor sites insufficient.
• External fixator or intramedullary transport nail used.
• Transport segment moved at 1 mm/day after latency; docking site grafted if needed.
• Long treatment time (1-2 months per cm) but excellent for large segmental loss.

Vascularised Bone Graft

• Free fibula or iliac crest for defects greater than 6 cm with poor local vascularity.
• Requires microsurgical expertise and healthy recipient vessels.
• Provides immediate structural support and living bone.

Decision Factors

Defect size, host class, soft-tissue quality, patient compliance and surgeon expertise determine the choice between Masquelet, transport and vascularised graft.

Post-operative Antimicrobial Therapy

• Duration: typically 6 weeks of pathogen-specific intravenous antibiotics followed by 2-6 months of oral suppression, guided by ID/microbiology.
• Route: IV initially for severe or resistant organisms; early switch to oral when clinical response and oral bioavailability allow.
• Monitoring: weekly CRP, renal function (for aminoglycosides/vancomycin), drug levels as indicated.
• Multidisciplinary input: mandatory infectious-disease consultation for complex or resistant infections.

Complications

Rehabilitation Protocol

Early Phase (0-6 weeks)

• Maintain external fixation or cast as indicated.
• Non-weight-bearing or touch weight-bearing until soft-tissue healing.
• Daily pin-site care; monitor for pin-site infection.
• Gentle ROM of adjacent joints; isometric muscle exercises.

Intermediate Phase (6-12 weeks)

• Progressive weight-bearing as bone transport or graft incorporates.
• Remove PMMA spacer/beads at 6-8 weeks if Masquelet planned; graft at same sitting.
• Transition to removable brace once stability allows.

Late Phase (3-12 months)

• Full weight-bearing when radiographic union confirmed.
• Strengthening, gait training, proprioception.
• Surveillance imaging and CRP every 3 months for first year, then annually.

Return to Function

• Sedentary work: 3-6 months.
• Manual labour: 6-12 months or longer with transport.
• Sport or high-impact: individualised, often restricted permanently after major reconstruction.